3.5 USD
-0.06 (-1.69%)
At close: Jan 30, 2026
3.5 USD
0 (0%)
After Hours: 1/30/2026, 8:04:10 PM
Overall MDXH gets a fundamental rating of 3 out of 10. We evaluated MDXH against 525 industry peers in the Biotechnology industry. MDXH may be in some trouble as it scores bad on both profitability and health. MDXH shows excellent growth, but is valued quite expensive already.
1. Profitability
1.1 Basic Checks
- MDXH had negative earnings in the past year.
- In the past year MDXH has reported a negative cash flow from operations.
- MDXH had negative earnings in each of the past 5 years.
- In the past 5 years MDXH always reported negative operating cash flow.
1.2 Ratios
- MDXH has a better Return On Assets (-33.59%) than 63.81% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -33.59% | ||
| ROE | N/A | ||
| ROIC | N/A |
ROA(3y)-31.55%
ROA(5y)-44.62%
ROE(3y)-441.71%
ROE(5y)-376.22%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
- The Gross Margin of MDXH (63.87%) is better than 79.81% of its industry peers.
- MDXH's Gross Margin has improved in the last couple of years.
- MDXH does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 63.87% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y9.37%
GM growth 5YN/A
2. Health
2.1 Basic Checks
- MDXH does not have a ROIC to compare to the WACC, probably because it is not profitable.
- Compared to 1 year ago, MDXH has more shares outstanding
- Compared to 5 years ago, MDXH has more shares outstanding
- The debt/assets ratio for MDXH is higher compared to a year ago.
2.2 Solvency
- MDXH has an Altman-Z score of -2.54. This is a bad value and indicates that MDXH is not financially healthy and even has some risk of bankruptcy.
- Looking at the Altman-Z score, with a value of -2.54, MDXH is in line with its industry, outperforming 48.95% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | N/A | ||
| Altman-Z | -2.54 |
ROIC/WACCN/A
WACC8.86%
2.3 Liquidity
- MDXH has a Current Ratio of 1.14. This is a normal value and indicates that MDXH is financially healthy and should not expect problems in meeting its short term obligations.
- With a Current ratio value of 1.14, MDXH is not doing good in the industry: 84.95% of the companies in the same industry are doing better.
- A Quick Ratio of 1.02 indicates that MDXH should not have too much problems paying its short term obligations.
- With a Quick ratio value of 1.02, MDXH is not doing good in the industry: 84.95% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.14 | ||
| Quick Ratio | 1.02 |
3. Growth
3.1 Past
- MDXH shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 57.89%, which is quite impressive.
- The Revenue has grown by 21.62% in the past year. This is a very strong growth!
- Measured over the past years, MDXH shows a very strong growth in Revenue. The Revenue has been growing by 50.17% on average per year.
EPS 1Y (TTM)57.89%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%60%
Revenue 1Y (TTM)21.62%
Revenue growth 3Y59.39%
Revenue growth 5Y50.17%
Sales Q2Q%17.65%
3.2 Future
- MDXH is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 27.55% yearly.
- MDXH is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 21.31% yearly.
EPS Next Y53.68%
EPS Next 2Y32.43%
EPS Next 3Y27.55%
EPS Next 5YN/A
Revenue Next Year22.89%
Revenue Next 2Y22.93%
Revenue Next 3Y21.68%
Revenue Next 5Y21.31%
3.3 Evolution
- Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
4. Valuation
4.1 Price/Earnings Ratio
- MDXH reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
- Also next year MDXH is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
- A more expensive valuation may be justified as MDXH's earnings are expected to grow with 27.55% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y32.43%
EPS Next 3Y27.55%
5. Dividend
5.1 Amount
- No dividends for MDXH!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
MDXHEALTH / MDXH FAQ
Can you provide the ChartMill fundamental rating for MDXHEALTH?
ChartMill assigns a fundamental rating of 3 / 10 to MDXH.
What is the valuation status of MDXHEALTH (MDXH) stock?
ChartMill assigns a valuation rating of 1 / 10 to MDXHEALTH (MDXH). This can be considered as Overvalued.
How profitable is MDXHEALTH (MDXH) stock?
MDXHEALTH (MDXH) has a profitability rating of 2 / 10.
Can you provide the expected EPS growth for MDXH stock?
The Earnings per Share (EPS) of MDXHEALTH (MDXH) is expected to grow by 53.68% in the next year.